Please, find us on Bluesky.
I will not support a platform whose owner, an unelected official, is actively damaging the US government including the NIH.
Complete Regression of Hepatoblastoma after Interleukin-15– and Interleukin-21–Coexpressing CAR T-Cell Therapy | New England Journal of Medicine https://t.co/Cy4JPaTOEl
@seattlechildren@TexasChildrens@NIH
A 3-year-old boy with chemotherapy-resistant metastatic hepatoblastoma had complete regression lasting at least 12 months after two infusions of glypican-3–specific CAR T cells coexpressing interleukin-15 and interleukin-21. Read the full correspondence: https://t.co/mygBCinUZq
Excited to share our work in @NEJM! A child with refractory hepatoblastoma achieved a durable complete response after IL-15/IL-21 GPC3 CAR T cells.
Grateful to the patient & family and @AndrasHeczey, @CAGT, @BCM, @TexasChildrens, @SeattleChildrens & @NIH!
https://t.co/Se1KjrV0ny
Please, find us on @bluesky .
I will not support a platform whose owner, an unelected official, is actively and ruthlessly damaging the US government including the NIH.
IL15 increases the expansion of CAR T cells and induces antitumor responses in patients with GPC3+ solid tumors (i.e. liver cancer).
https://t.co/ybNobLrQvy